Vascular Cognitive Impairment(Vascular Cognitive Impairment no dementia and Vascular Dementia)
Conditions
Interventions
Fluoxetine +VaD:Fluoxetine 20mg q.d. po+secondary p-revention of stroke for 12 weeks
Control+VaD:Secondary prevention of stroke for 12 weeks
Fluoxetine+VCIND:Fluoxetine 20mg q.d. po+secondary p-revention of stroke for 12 weeks
Control +VCIND:Secondary prevention of stroke for 12 weeks
Sponsors
Zhongnan Hospital, Wuhan University
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: The VCIND criteria includes six conditions 1. age 45–80 years; 2. the subjects have the histor-y of stroke and/or the neuroimaging (CT or MRI) showes evidence of cerebrovascular diseas-e; 3. the subjects’ cognitive impairment does not meet the DSM-IV criteria for dementia; 4. cognitive impairment is judged to have a vascular cause and Hachinski Ischemic Score is greater than 7; 5. the requirement for a cognitive de?cit to cause functional decits is de?ned operationally as follows: global functional impairment is deyned as having difficulty in any two of the following domains: performing household chores,managing money, feeding self, dressing, and incontinence; 6. written informed consent was obtained from each participant. The VD criteria includes four conditions: (1) age 45–80 years; (2) the subjects have the history of stroke and/or the neuroimaging (CT or MRI) showes evidence of cerebrovascular disease; (3) the subjects' cognitive impairment meet the DSM-IV criteria for dementia; (4) cognitive impair-ment is judged to have a vascular cause and Hachinski Ischemic Score (HIS) is greater than 7; (5) written informed consent was obtained from each participant.
Exclusion criteria
Exclusion criteria: 1. if they meet DSM-IV diagnostic criteria for depressive disorder; 2. if they have any of the following conditions: heart failure, respiratory failure, other or-gan failure,pregnancy and tumor; 3. if they have history of degenerative diseases, including Pa-rkinson's disease,Alzheimer's disease, Multiple System Atrophy and Huntington's disease; 4. if they are unable to attend neuropsychological tests due to severe aphasia; 5. if they have hist-ory of alcohol and other drugs abuse, or have used anticholinesterase, anticoagulants or other drugs that can improve cognition within one year prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain-derived neurotrophic factor;Vascular endothelial growth factor;Mini-Mental State Examination;ADAS-cog;FAB (frontal assessment battery);Stroop Test;CDT;Verbal Fluency Test;Trail Making Test Form A;Trail Making Test Form B;Digit span; | — |
Countries
China
Contacts
Public ContactZhang Junjian
Outcome results
None listed